Citigroup
AKCA

Citigroup’s Akcea Therapeutics Inc AKCA Stock Holding History

Citigroup’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-220,124
Closed -$3.99M – 7814
2020
Q3 		$3.99M Buy
220,124
+204,717
+1,329% +$2.9M ﹤0.01% 2057
2020
Q2 		$211K Buy
15,407
+5,849
+61% +$90.2K ﹤0.01% 4976
2020
Q1 		$137K Sell
9,558
-621
-6% -$10.2K ﹤0.01% 5074
2019
Q4 		$172K Buy
10,179
+4,862
+91% +$90.5K ﹤0.01% 5315
2019
Q3 		$82K Sell
5,317
-27,131
-84% -$578K ﹤0.01% 5813
2019
Q2 		$761K Sell
32,448
-1,658
-5% -$41K ﹤0.01% 3982
2019
Q1 		$966K Buy
34,106
+22,806
+202% +$664K ﹤0.01% 3434
2018
Q4 		$341K Buy
11,300
+8,720
+338% +$244K ﹤0.01% 4513
2018
Q3 		$90K Buy
+2,580
New +$78.1K ﹤0.01% 6014
2018
Q2 		– Sell
-125
Closed -$3K – 7815
2018
Q1 		$3K Sell
125
-4
-3% -$86 ﹤0.01% 7325
2017
Q4 		$2K Buy
+129
New +$2.53K ﹤0.01% 7427

Citigroup's AKCA Position: Q4 2020 in Review

Citigroup sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 220,124 shares — an estimated $3.99M sold.

Citigroup first reported a position in AKCA in Q4 2017 and held it in 11 quarters. The position peaked at $3.99M in Q3 2020. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • Citigroup reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • Citigroup sold 220,124 Akcea Therapeutics Inc shares in Q4 2020, an estimated $3.99M.
  • Citigroup first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 11 quarters.
  • Citigroup's Akcea Therapeutics Inc position peaked at $3.99M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Citigroup's 13F filing for Q4 2020, filed 11 Feb 2021.